Arvind Dasari, MD, MS

A3: SUNLIGHT Impact (2/2) It also means in the past 6 months we have data that will improve survival for mCRC to 7.7 months🔥🔥🔥 (5.1 months with SUNLIGHT and 2.6 months with FRESCO-2 which looked at fruquintinib!) @adasarimd #CRCTrialsChat @OncoAlert #CRCSM

Day #3 #GI23 #crc and anal #cancer updates! Come visit our #QOL data from phase 3 trial #FRESCO2 @hutchmed of #fruquinitinb vs. placebo #Abs 67 (D4) today (pending FDA review for new possible option for our patients)! @adasarimd @VUMC_MD @VUMC_Cancer @VUMCHemOnc @MDAndersonNews

#GI23 #ascogi23 @adasarimd @hutchmed #FRESCO-2 #Fruquintinib #QOL Board D4 Happening now: #teamwork #mentorship #workfamily @VUMC_Cancer @VUMCHemOnc @VUMC_MD @MDAndersonNews #cancer #CancerResearch #patientcare #movingtheneedleforward #ClinicalTrials

.@SWOG S1815 results @ #ASCOGI23: Adding nab-paclitaxel to standard gem-cis for patients w advanced #biliary tract cancers did not signif. improve median OS but may benefit patients w locally advanced disease or gallbladder adenocarcinoma. @rachnatshroff swog.org/news-events/ne…

NRG-GI008, CIRCULATE-US For St III & high risk st II Colon cancer All pts get ctDNA test 6-8 wks after surgery If ctDNA +ve, randomized to 📌 CAPOX or FOLFOX --SOC or 📌FOLFOXIRI--stronger chemo To see if strong chemo➡️to better outcomes in ctDNA+ve pts #CRCTrialsChat 3/3

NRG-GI008, CIRCULATE-US For St III & some st II Colon ca All pts get ctDNA test after surgery If ctDNA -ve, randomized to 📌 FOLFOX/CAPOX or 📌No chemo with serial ctDNA testing If ctDNA+ve in the no chemo arm later, cross-over to the ctDNA +ve arm #CRCTrialsChat 2/3

NRG-GI008, CIRCULATE-US is a #clinicaltrial for st III & high-risk st II colon cancer 📌To see if chemo is needed for all or only some patients & 📌if chemo is needed, what kind? based on #ctDNA +ve or -ve after surgery More info👇👇 nrgoncology.org/CIRCULATE-US #CRCTrialsChat 1/3

It takes a village! Management of metastatic CRC has become ⬆️complex and requires a multidisciplinary team of caregivers. I am proud to have served w/ @CathyEngMD as co-chair for the @ASCO panel that developed these guidelines for metastatic CRC in @JCO_ASCO . (🧵)

🔑 points: 1⃣CapeTem was associated with a signif improvement in PFS compared to Tem 2⃣Median PFS & RR with CapeTem are the highest reported in a randomized trial for advanced pNET 3⃣MGMT deficiency was associated with response to Tem, though not recommended for routine use 2/